Gritstone Oncology is extending gains today after a mammoth rally on Tuesday as the company has joined the COVID-19 vaccine bandwagon. In pre-market trading on the stock market today, GRTS stock jumped 10.01%, near $24.50. During the regular session, Gritstone stock rose 248.51% to $22.27, bringing its year-to-date performance at 465%.
California-based biotech company Gritstone Oncology announced that it has started human trials for its COVID-19 vaccine nicknamed CORAL. This biotech firm which merely focuses on cancer vaccinations using common practices is currently working on the COVID-19 vaccine. The comparison between this vaccine and others is that Gritstone believes that their version can work to combat mutations found in the COVID-19 genome which is plaguing various countries.
Bill & Melinda Gates Foundation will provide the financial and logistical infrastructure by working alongside the National Institute of Allergy and Infectious Diseases(NIAID). This collaboration will help boost Gritstone Oncology’s future potentials.
Gritstone Oncology will employ its EDGE tech to build the parameters for the COVID-19 vaccine. Using machine learning EDGE can predict antigens which are been infected by cells and are going to be infected by viral cells that an immune system hardly detects. Gritstone believes that their vaccine may provide a more compatible solution than the alternatives as they use a better ratio of T cell count and neutralize infected cells faster.
Current vaccines have no sign if they provide long-term immunity. In order to reach this milestone, Gritstone believes that further testing and trials should be used in order to suppress the ongoing pandemic losses. The basis for any vaccine must be an ability to induce antibodies and have the sensory input from the T cell count to provide immunity for future attacks. Gritstone Oncology firmly believes in this endeavor and plans to pursue its due course in the future.